Featured Research

from universities, journals, and other organizations

Early study analysis suggests exemestane reduces breast density in high risk postmenopausal women

Date:
December 9, 2010
Source:
Georgetown University Medical Center
Summary:
A drug that shows promise for preventing breast cancer in postmenopausal women with an increased risk of developing the disease, appears to reduce mammographic breast density in the same group of women. Having dense breast tissue on mammogram is believed to be one of the strongest predictors of breast cancer.

A drug that shows promise for preventing breast cancer in postmenopausal women with an increased risk of developing the disease, appears to reduce mammographic breast density in the same group of women. Having dense breast tissue on mammogram is believed to be one of the strongest predictors of breast cancer. The preliminary analysis from the small, phase II study was presented December 9 at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in Texas.

The ongoing study at Georgetown Lombardi Comprehensive Cancer Center and the Center for Cancer Research at the National Cancer Institute examines the effect of exemestane (Aromasinฎ) on breast density. Exemestane is in a class of medications called aromatase inhibitors (AI). It works by decreasing the amount of estrogen produced by the body. This can slow or stop the growth of some breast tumors that need estrogen to grow.

In this study, a preliminary analysis was conducted for the first 23 participants enrolled (42 women were enrolled as of June 2010). Mammograms were taken before the women began exemestane and one year after treatment started. Breast density was compared between the two mammograms for each woman.

"Overall, we saw a seven percent decrease in mammographic density among the women, a statistically significant finding," says Jennifer Eng-Wong, M.D., M.P.H., assistant professor of oncology at Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center. "Previous studies with AIs in high risk women have not shown a significant decline in mammographic density and differences in results may be due to duration of treatment or baseline characteristics of the study population."

She says earlier studies with tamoxifen, an FDA-approved drug to reduce breast cancer risk in women at high risk, also reduced breast density. A change in breast density appears to be an intermediate marker for breast cancer. For example a 10 percent drop in breast density was correlated with a 50 percent drop in breast cancer incidence. Tamoxifen is in a different class of drugs. Side-effects of taking it have deterred women from choosing tamoxifen, resulting in a need for other treatment options such as aromatase inhibitors. In general, both of these agents are well tolerated, however rare serious side effects of tamoxifen include thrombo-embolic disease and endometrial cancer. The AIs are not associated with these side effects but have been associated with an increased risk of bone fracture and loss of bone density.

Women who were eligible for the study had an increased risk of breast cancer defined as one of the following: five year Gail model of risk ≥1.7 percent, a high risk breast lesion (e.g. lobular neoplasia or ductal carcinoma in situ), a known BRCA1/2 mutation, or a prior stage I/II breast cancer with treatment completed two years prior to enrolling in the study. Women were excluded if testing revealed osteoporosis.

Eng-Wong points out that this stage of the analysis does not include a control group (women not taking exemestane) with whom the current findings could be compared, but she says a matched control comparison is planned. The study will continue until an analysis can be conducted on mammographic density after two years of treatment.

In addition to Eng-Wong authors include Claudine Isaacs, Robert Warren, Philip Cohen and Celia Byrne at Georgetown Lombardi; and David Venzon, Suparna Wedam, Jo Anne Zujewski and Larissa Korde at the NCI.

This research is funded by the NCI Intramural Research Program and Georgetown Lombardi. Pfizer supplied the exemestane used in the study. Eng-Wong reports having no personal financial interests related to the study.


Story Source:

The above story is based on materials provided by Georgetown University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Georgetown University Medical Center. "Early study analysis suggests exemestane reduces breast density in high risk postmenopausal women." ScienceDaily. ScienceDaily, 9 December 2010. <www.sciencedaily.com/releases/2010/12/101209185552.htm>.
Georgetown University Medical Center. (2010, December 9). Early study analysis suggests exemestane reduces breast density in high risk postmenopausal women. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2010/12/101209185552.htm
Georgetown University Medical Center. "Early study analysis suggests exemestane reduces breast density in high risk postmenopausal women." ScienceDaily. www.sciencedaily.com/releases/2010/12/101209185552.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WHO Calls for Ban on E-Cigarette Sales to Minors

WHO Calls for Ban on E-Cigarette Sales to Minors

AFP (Aug. 26, 2014) — The World Health Organization called Tuesday on governments should ban the sale of e-cigarettes to minors, warning that they pose a "serious threat" to foetuses and young people. Duration: 01:44 Video provided by AFP
Powered by NewsLook.com
Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Newsy (Aug. 26, 2014) — A study published in the journal "Neurology" interviewed more than 19,000 people and found 15 percent suffer from being "sleep drunk." Video provided by Newsy
Powered by NewsLook.com
Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Newsy (Aug. 26, 2014) — A new study found fewer deaths from prescription drug overdoses in states that have legalized medical marijuana. But experts disagree on the results. Video provided by Newsy
Powered by NewsLook.com
Official: British Ebola Sufferer Receiving Experimental Drug

Official: British Ebola Sufferer Receiving Experimental Drug

AFP (Aug. 26, 2014) — A British nurse infected with Ebola while working in Sierra Leone is being given the same experimental drug used on two US missionaries who have recovered for the disease, doctors in London say. Duration: 00:44 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:  

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile iPhone Android Web
    Follow Facebook Twitter Google+
    Subscribe RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins